Theratechnologies expands peptide portfolio in endocrinology.
Walczak
Irene M
IM
D000279:Administration, Cutaneous; D017322:Clinical Trials, Phase II as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005934:Glucagon / Q000008:administration & dosage / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D011498:Protein Precursors / Q000008:administration & dosage / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon